LenvaRx- lenvatinib as maintenance in cervical cancer

The Impact of Lenvatinib and Bevacizumab on Chemotherapy Outcomes in recurrent/metastatic Cervical Cancer:A Non-Inferiority Trial - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072134

Enrollment

145

Registered

2024-08-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Lenvatinib: Multikinase VEGF inhibitor Dose 8mg per oral till progression Control Intervention1: Bevacizumab: VEGF 1 inhibitor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Histologically confirmed diagnosis of recurrent(not amenable for local treatment) or metastatic cervical cancer. 2.Have measurable disease based on RECIST. 3.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

Exclusion criteria

Exclusion criteria: Uncontrolled blood pressure (BP) Pregnant, or breastfeeding patient. Major surgery in last 6 weeks. H/O CVA/ MI or any hemorrhagic episode in last 12 months or on active anti platelet drugs.

Design outcomes

Primary

Measure	Time frame
PFSTimepoint: 2 year	—

Secondary

Measure	Time frame
OS Incidence of adverse Incidence of study drug discontinuation due to Adverse Events Timepoint: 3 monthly duration 2 year	—

Countries

India

Contacts

Public ContactAseem Samar

Bhagwan mahavir cancer hospital & research centre

aseemtmh@gmail.com9004399604

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026